Related Experiment Video
Updated: Jun 12, 2026

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
Published on: August 11, 2018
Translation and validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in Denmark
Anne M Clausen1,2, Brian T Kornblit3, Maria T Larsen3
1Department of Haematology, Odense University Hospital.
Introduction:
Chronic graft-versus-host disease (cGVHD) impairs quality of life after allogeneic haematopoietic stem cell transplantation. This study aimed to translate the Lee cGVHD Symptom Scale, a validated patient-reported outcome measure, into Danish and evaluate its psychometric properties.
Methods:
The scale was translated using forward-backward translation and cognitive debriefing interviews. Questionnaire data from the Danish version were collected at baseline and after 7-10 days. Construct validity was assessed with exploratory factor analysis (EFA), convergent and divergent validity by correlations with the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) and the Common Terminology of Cancer-related Adverse Events (PRO-CTCAE). Internal consistency was assessed using Cronbach's alpha, and test-retest reliability using intraclass correlation coefficients (ICC).
Results:
A total of 72 patients participated; 65 completed the test-retest. EFA supported a six-factor structure, with some deviations from the original subscales. Cronbach's alpha for the total scale was good (0.86). The test-retest ICC ranged from 0.23 to 0.93. Most hypothesised correlations for convergent and divergent validity were confirmed.
Conclusions:
The Danish Lee cGVHD Symptom Scale is a valid and reliable instrument for assessing cGVHD symptoms. Overall consistency and reliability were acceptable, though refinement of some subscales is recommended. The scale is suitable for both clinical and research use in Danish cGVHD populations, with further validation suggested in larger samples.
Funding:
The Joint Research Fund of Odense University Hospital and Rigshospitalet. Funding no.: 83-A3982.
Trial Registration:
Not relevant.
